Towards Predicting the Biodiversity Impacts of Environmental Change

Award

Buyers

Value

£250,000

Suppliers

Classifications

  • Research and development services and related consultancy services

Tags

  • award

Submission Deadline

1 year ago

Published

1 year ago

Description

In November 2022, JNCC and the Statutory Nature Conservation Bodies published a joint statement on Nature Recovery. This set out the need to embed nature recovery in UK decision-making and to deliver impactful policies that incentivise and drive public and private investment in the protection and recovery of the UK's nature through all our activities. As envisaged in that statement, the global community has now committed to the ambitious Kunming-Montreal Global Biodiversity Framework. In May 2023, JNCC published a new strategy: Together for Nature (https://jncc.gov.uk/about-jncc/our-strategy); this further set out the need to advise on the design of new policies and actions to progress nature recovery. However, despite a strong evidence base on biodiversity in the UK, we currently lack the technical capability to use this evidence to model the impact of potential environmental, societal and policy trajectories on biodiversity.

Documents

Premium

Bypass the hassle of outdated portals. Get all the information you need right here, right now.

  • Contract Agreement

    The official contract terms, conditions, and scopes of work.

    Download

  • Award Notice

    Details on the tender award and selected suppliers.

    Download

Similar Contracts

Open

Early Retirement Cohort - Inactivity Trailblazer Programme

YNYCA is seeking to commission a specialist external provider to deliver a piece of qualitative research into economic inactivity within persons who may identify as having taken early retirement in York and North Yorkshire This research will support the Trailblazer programme's ambitions to reduce economic inactivity in the region, inform future interventions, and contribute to the wider understanding of economic inactivity in the region

Katy Reed

Katy Reed

Published 1 hour ago
Open

A Health Economic Evaluation Framework And Bespoke Analysis For AMR Diagnostic Technologies

PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. The PACE programme is looking for an external provider to deliver an 'Enabling Project' in partnership related to early health economic analysis to support our cohort of AMR diagnostic innovation developers from our 2nd PACE funding call. Please see (https://paceamr.org.uk/news/ukhsa-announced-as-first-pace-collaboration-to-help-tackle-deadly-antimicrobial-resistance/) for details of our first enabling project partnering with UKHSA to provide access to clinical isolates for our first cohort of therapeutics developers. The overall purpose of this second enabling project is to provide PACE awardees and the wider AMR community with access to practical early-stage health economic outputs, including care pathway insights, indicative cost analyses, early-stage economic modelling and value proposition frameworks tailored to our cohorts emerging diagnostic technologies. These outputs will be designed to support product development decisions, stakeholder engagements and future reimbursement planning with relevance across bloodstream infections (BSI), respiratory tract infections (RTI) and urinary tract infections (UTI). To maximise impact, the provider is expected to group diagnostics with similar clinical positioning or use cases together to make the most of synergies across the cohort (e.g. when establishing the existing care pathway of the indications). Where relevant, the provider is also expected to align with existing or ongoing initiatives. A key priority is to ensure that insights, and findings from the project are made publicly available through open-access tools, share reports etc. to ensure that it benefits the broader AMR innovation community to inform future policy, funding and procurement decisions. The support required is across three work packages: Kick-off webinar: Introduce PACE awardees (diagnostics projects) to early-stage health economic assessment including its purpose, relevance and application across the cohort. Baseline development and modelling tool: Deliver care-pathway analyses (BSI, RTI and UTI) and a re-usable (modelling with guidance -enabling scenario testing using default assumptions. Project-specific deployment: Collaborate with each PACE project to input diagnostic specific data, generate tailored analyses, and refine the tool using real-world examples.

Katy Reed

Katy Reed

Published 1 hour ago
Open

A Health Economic Evaluation Framework And Bespoke Analysis For AMR Diagnostic Technologies

PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. The PACE programme is looking for an external provider to deliver an 'Enabling Project' in partnership related to early health economic analysis to support our cohort of AMR diagnostic innovation developers from our 2nd PACE funding call. Please see (https://paceamr.org.uk/news/ukhsa-announced-as-first-pace-collaboration-to-help-tackle-deadly-antimicrobial-resistance/) for details of our first enabling project partnering with UKHSA to provide access to clinical isolates for our first cohort of therapeutics developers. The overall purpose of this second enabling project is to provide PACE awardees and the wider AMR community with access to practical early-stage health economic outputs, including care pathway insights, indicative cost analyses, early-stage economic modelling and value proposition frameworks tailored to our cohorts emerging diagnostic technologies. These outputs will be designed to support product development decisions, stakeholder engagements and future reimbursement planning with relevance across bloodstream infections (BSI), respiratory tract infections (RTI) and urinary tract infections (UTI). To maximise impact, the provider is expected to group diagnostics with similar clinical positioning or use cases together to make the most of synergies across the cohort (e.g. when establishing the existing care pathway of the indications). Where relevant, the provider is also expected to align with existing or ongoing initiatives. A key priority is to ensure that insights, and findings from the project are made publicly available through open-access tools, share reports etc. to ensure that it benefits the broader AMR innovation community to inform future policy, funding and procurement decisions. The support required is across three work packages: Kick-off webinar: Introduce PACE awardees (diagnostics projects) to early-stage health economic assessment including its purpose, relevance and application across the cohort. Baseline development and modelling tool: Deliver care-pathway analyses (BSI, RTI and UTI) and a re-usable (modelling with guidance -enabling scenario testing using default assumptions. Project-specific deployment: Collaborate with each PACE project to input diagnostic specific data, generate tailored analyses, and refine the tool using real-world examples.

Katy Reed

Katy Reed

Published 1 hour ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Organisation

Joint Nature Conservation Committee

Body governed by public law

[email protected]

441733562626

Timeline complete

Publish
Bid
Evaluate
Award
Complete